The earnings call highlighted significant progress in clinical studies and strategic partnerships, particularly with JCR Pharmaceuticals, which is expected to enhance their Alzheimer's treatment portfolio. Financially, the company maintains a strong cash position, although increased R&D expenses and operational losses were noted. The overall sentiment around Alzheimer's therapies is positive, with advancements in diagnostics and treatments. Despite financial challenges, the strategic and clinical advancements suggest a positive outlook.

Company Guidance -

Q3 2025

During the Acumen Pharmaceuticals Second Quarter 2025 Conference Call, the company provided guidance on several key metrics and strategic initiatives. Notably, Acumen reported having $166.2 million in cash and marketable securities as of June 30, 2025, which is expected to support their clinical and operational activities into early 2027. R&D expenses for the second quarter were $37.1 million, reflecting an increase due to manufacturing and clinical trial activities. Additionally, General and Administrative expenses remained stable at $4.6 million. Acumen anticipates top-line results from the Phase II AlTiTUAD study in late 2026, with expectations for key efficacy and safety measures. The company also highlighted a strategic collaboration with JCR Pharmaceuticals, aimed at developing next-generation Alzheimer's treatments, with potential milestone payments up to $555 million, emphasizing their capital-efficient portfolio expansion strategy.

Phase II AlTiTUAD Study Progress

The company made significant progress with their Phase II AlTiTUAD study, receiving positive feedback on study design and patient retention. They expect top-line results in late 2026.

Strategic Partnership with JCR Pharmaceuticals

Acumen Pharmaceuticals announced a strategic collaboration with JCR Pharmaceuticals to develop an Alzheimer's disease product, combining their antibody expertise with JCR's blood-brain barrier-penetrating technology.

Financial Position and Collaboration Value

The company reported $166.2 million in cash and marketable securities, enough to support operations into early 2027. The collaboration with JCR is capital efficient, with potential milestone payments up to $555 million.

Positive Feedback on Alzheimer's Disease Therapies

There is a positive sentiment around current Alzheimer's therapies and potential for next-generation treatments, with improvements in clinical infrastructure and diagnostic options.

Acumen Pharmaceuticals (ABOS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABOS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.55 / -	-0.5	―	―	―
Aug 12, 2025	2025 (Q2)	-0.49 / -0.68	-0.34	-100.00% (-0.34)	―
May 13, 2025	2025 (Q1)	-0.73 / -0.48	-0.25	-92.00% (-0.23)
Mar 27, 2025	2024 (Q4)	-0.51 / -0.62	-0.28	-121.43% (-0.34)
Nov 12, 2024	2024 (Q3)	-0.36 / -0.50	-0.24	-108.33% (-0.26)
Aug 13, 2024	2024 (Q2)	-0.28 / -0.34	-0.28	-21.43% (-0.06)
May 14, 2024	2024 (Q1)	-0.26 / -0.25	-0.28	10.71% (+0.03)	―
Mar 26, 2024	2023 (Q4)	-0.27 / -0.28	-0.32	12.50% (+0.04)	―
Nov 13, 2023	2023 (Q3)	-0.26 / -0.24	-0.26	7.69% (+0.02)
Aug 08, 2023	2023 (Q2)	-0.35 / -0.28	-0.25	-12.00% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABOS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$1.42	$1.26	-11.27%
May 13, 2025	$1.05	$1.05	0.00%
Mar 27, 2025	$1.16	$1.23	+6.03%
Nov 12, 2024	$3.22	$2.68	-16.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Acumen Pharmaceuticals, Inc. (ABOS) report earnings?

Acumen Pharmaceuticals, Inc. (ABOS) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Acumen Pharmaceuticals, Inc. (ABOS) earnings time?

Acumen Pharmaceuticals, Inc. (ABOS) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABOS EPS forecast?

ABOS EPS forecast for the fiscal quarter 2025 (Q3) is -0.55.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing